Navigation Links
Study reveals potential immune benefits of vitamin D supplements in healthy individuals
Date:3/20/2013

(Boston) Research from Boston University School of Medicine (BUSM) shows that improving vitamin D status by increasing its level in the blood could have a number of non-skeletal health benefits. The study, published online in PLOS ONE, reveals for the first time that improvement in the vitamin D status of healthy adults significantly impacts genes involved with a number of biologic pathways associated with cancer, cardiovascular disease (CVD), infectious diseases and autoimmune diseases. While previous studies have shown that vitamin D deficiency is associated with an increased risk for the aforementioned diseases, these results go a step further and provide direct evidence that improvement in vitamin D status plays a large role in improving immunity and lowering the risk for many diseases.

Vitamin D is unique in that it can be both ingested and synthesized by the body with sun exposure. It is then converted by both the liver and kidneys to a form that the body can use. An individuals' level of vitamin D, or their vitamin D status, is determined by measuring the level of 25-hydroxyvitamin D in the blood. Vitamin D deficiency, which is defined as a status of less than 20 nanograms per milliliter (ng/mL) of 25-hydroxyvitamin D, can cause a number of health issues, including rickets and other musculoskeletal diseases. Recently, however, data suggests that vitamin D deficiency (<20 ng/mL) and vitamin D insufficiency (between 21-29 ng/mL) is linked to cancer, autoimmune diseases, infectious diseases, type 2 diabetes and cardiovascular disease.

The randomized, double-blind, single-site pilot trial involved eight healthy men and women with an average age of 27 who were vitamin D deficient or insufficient at the start of the trial. Three participants received 400 International Units (IUs) of vitamin D per day and five received 2,000 IUs per day for a two-month period. Samples of white blood cells (immune cells) were collected at the beginning of the two-month period and again at the end. A broad gene expression analysis was conducted on these samples and more than 22,500 genes were investigated to see if their activity increased or decreased as a result of the vitamin D intake.

At the end of the pilot, the group that received 2000 IUs achieved a vitamin D status of 34 ng/mL, which is considered sufficient, while the group that received 400 IUs achieved an insufficient status of 25 ng/mL.

The results of the gene expression analysis indicated statistically significant alterations in the activity of 291 genes. Further analysis showed that the biologic functions associated with the 291 genes are related to 160 biologic pathways linked to cancer, autoimmune diseases, infectious diseases and CVD.

Examining gene response elements, or sequences of DNA bases that interact with vitamin D receptors to regulate gene expression, they also identified new genes related to vitamin D status. To ensure that their observations were accurate, the researchers looked at 12 genes whose level of expression does not change, and those genes remained stable throughout the trial period.

"This study reveals the molecular fingerprints that help explain the non-skeletal health benefits of vitamin D," said Michael F. Holick, PhD, MD, professor of medicine, physiology and biophysics at BUSM and leading vitamin D expert who served as the study's corresponding author. "While a larger study is necessary to confirm our observations, the data demonstrates that improving vitamin D status can have a dramatic effect on gene expression in our immune cells and may help explain the role of vitamin D in reducing the risk for CVD, cancer and other diseases."


'/>"/>

Contact: Jenny Eriksen
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... , ... June 28, 2017 , ... David B. Sosin, a founding partner ... took over the post of 2nd Vice President for the Illinois State Bar Association ... as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces ... of the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer ... as a regional supplier of garden pea seed. As demand grew, the small company ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
Breaking Medicine Technology: